Physician profile
Dana Brown-Acker
NPI 1275044331
$329.95
in general payments reported to CMS, 2019-2025
9 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $28.37 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $91.20 | 2025 | |
| Astellas Pharma US INC | $76.99 | 2025 | Veozah |
| Corcept Therapeutics | $36.92 | 2025 | Korlym |
| Genzyme Corporation | $28.37 | 2024 | |
| Axsome Therapeutics, INC. | $25.39 | 2025 | Auvelity |
| Lilly USA, LLC | $21.95 | 2025 | Mounjaro |
| Novo Nordisk INC | $17.47 | 2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $17.24 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $14.42 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Brown-Acker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.